Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and drug candidate nimacimab, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Skye Bioscience securities between November 4, 2024, and October 3, 2025 [1]. - The lawsuit seeks to recover losses under federal securities laws due to misleading statements about the effectiveness and prospects of the drug candidate nimacimab [3]. Group 2: Investor Information - Investors who purchased Skye Bioscience securities during the Class Period and suffered losses have until January 16, 2026, to seek appointment as lead plaintiff [2]. - Interested investors can contact Johnson Fistel, PLLP for more information regarding their rights and potential recovery options [2]. Group 3: Allegations Against Skye Bioscience - The lawsuit alleges that Skye Bioscience failed to disclose that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [3]. - The true details regarding the drug's effectiveness were revealed on October 3, 2025, resulting in substantial damages for investors [3]. Group 4: Law Firm Background - Johnson Fistel, PLLP is a recognized shareholder rights law firm with a strong track record, having recovered approximately $90.7 million for investors in 2024 [4].